Crinetics Pharmaceuticals - CRNX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $62.50
  • Forecasted Upside: 37.12%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$45.58
▲ +1.37 (3.10%)

This chart shows the closing price for CRNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Crinetics Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRNX

Analyst Price Target is $62.50
▲ +37.12% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $62.50, with a high forecast of $97.00 and a low forecast of $35.00. The average price target represents a 37.12% upside from the last price of $45.58.

This chart shows the closing price for CRNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Crinetics Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$80.00 ➝ $80.00Low
6/4/2024OppenheimerBoost TargetOutperform ➝ Outperform$55.00 ➝ $74.00Low
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00Low
5/23/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$52.00 ➝ $62.00Low
5/23/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$50.00 ➝ $70.00Low
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00Low
5/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00Low
5/10/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$80.00Low
5/7/2024Piper SandlerBoost TargetOverweight ➝ Overweight$56.00 ➝ $97.00Low
3/28/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$80.00N/A
3/20/2024OppenheimerBoost TargetOutperform ➝ Outperform$54.00 ➝ $55.00Low
3/20/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$60.00 ➝ $80.00Low
3/20/2024JonestradingBoost TargetBuy ➝ Buy$52.00 ➝ $56.00Low
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00Low
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00Low
3/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$48.00 ➝ $54.00Low
3/6/2024CitigroupInitiated CoverageBuy$68.00Low
3/4/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$50.00 ➝ $65.00Low
2/29/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $60.00Low
2/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$46.00 ➝ $48.00Low
2/29/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$45.00 ➝ $52.00Low
2/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
1/16/2024Morgan StanleyInitiated CoverageOverweight$50.00Low
12/21/2023Jefferies Financial GroupInitiated CoverageHold$35.00Low
12/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
12/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$42.00Low
12/4/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$35.00Low
10/24/2023Cantor FitzgeraldReiterated RatingOverweight$52.00 ➝ $50.00Low
9/11/2023Evercore ISIBoost TargetOutperform ➝ Outperform$41.00 ➝ $48.00Low
9/11/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$43.00 ➝ $45.00Low
9/11/2023OppenheimerBoost TargetOutperform ➝ Outperform$40.00 ➝ $46.00Low
9/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$33.00Low
8/30/2023OppenheimerInitiated CoverageOutperform$40.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00Low
8/9/2023Robert W. BairdLower Target$48.00 ➝ $43.00Low
8/9/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$43.00 ➝ $42.00Low
8/9/2023HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $33.00Low
5/5/2023JMP SecuritiesBoost Target$41.00 ➝ $43.00Low
4/24/2023Piper SandlerInitiated CoverageOverweight$56.00Low
3/29/2023Robert W. BairdInitiated CoverageOutperform$48.00Low
3/27/2023Lifesci CapitalReiterated RatingOutperformLow
3/1/2023HC WainwrightReiterated RatingBuy$35.00Low
3/1/2023JMP SecuritiesLower TargetMarket Outperform$50.00 ➝ $41.00Low
5/26/2022SVB LeerinkBoost TargetOutperform$36.00 ➝ $39.00Medium
4/6/2022JMP SecuritiesReiterated RatingBuy$45.00Low
3/31/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/31/2022JMP SecuritiesBoost TargetMarket Outperform$43.00 ➝ $45.00High
1/5/2022JMP SecuritiesReiterated RatingBuy$43.00High
11/30/2021JMP SecuritiesInitiated CoverageOutperform$43.00High
11/23/2021Evercore ISIInitiated CoverageOutperformHigh
11/8/2021HC WainwrightBoost TargetBuy$30.00 ➝ $35.00Low
9/28/2021HC WainwrightReiterated RatingBuy$30.00Medium
9/16/2021JonestradingReiterated RatingBuy$45.00Low
6/18/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$28.00High
5/31/2021SVB LeerinkReiterated RatingBuy$33.00Medium
5/3/2021JonestradingInitiated CoverageBuy$42.00Medium
4/1/2021SVB LeerinkReiterated RatingBuy$33.00High
11/23/2020Cantor FitzgeraldBoost TargetOverweight$38.00 ➝ $42.00High
11/9/2020HC WainwrightReiterated RatingBuyLow
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
5/22/2020HC WainwrightReiterated RatingBuy$35.00 ➝ $30.00High
5/11/2020Cantor FitzgeraldBoost TargetAccumulate ➝ Overweight$28.00 ➝ $38.00High
4/3/2020HC WainwrightReiterated RatingBuy$35.00Medium
3/18/2020Cantor FitzgeraldReiterated RatingOverweightLow
3/11/2020HC WainwrightReiterated RatingBuyMedium
12/23/2019Roth CapitalInitiated CoverageBuy$37.00High
11/21/2019HC WainwrightReiterated RatingBuy$35.00Low
(Data available from 6/23/2019 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2024
  • 28 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/25/2024
  • 15 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024
  • 12 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
5/24/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024

Current Sentiment

  • 16 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $45.58
Low: $43.76
High: $46.16

50 Day Range

MA: $46.28
Low: $42.12
High: $51.91

52 Week Range

Now: $45.58
Low: $15.76
High: $53.70

Volume

2,277,293 shs

Average Volume

685,128 shs

Market Capitalization

$3.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Crinetics Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Crinetics Pharmaceuticals in the last year: Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Jonestrading, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, and Robert W. Baird.
View the latest analyst ratings for CRNX.

What is the current price target for Crinetics Pharmaceuticals?

12 Wall Street analysts have set twelve-month price targets for Crinetics Pharmaceuticals in the last year. Their average twelve-month price target is $62.50, suggesting a possible upside of 37.1%. Piper Sandler has the highest price target set, predicting CRNX will reach $97.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $35.00 for Crinetics Pharmaceuticals in the next year.
View the latest price targets for CRNX.

What is the current consensus analyst rating for Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CRNX.

What other companies compete with Crinetics Pharmaceuticals?

How do I contact Crinetics Pharmaceuticals' investor relations team?

Crinetics Pharmaceuticals' physical mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company's listed phone number is (858) 450-6464 and its investor relations email address is [email protected]. The official website for Crinetics Pharmaceuticals is www.crinetics.com. Learn More about contacing Crinetics Pharmaceuticals investor relations.